Stamos Capital Partners L.P. Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Stamos Capital Partners L.P. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,580 shares of the medical research company’s stock, valued at approximately $1,490,000.

Other large investors have also bought and sold shares of the company. Synergy Asset Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at $33,000. Lee Danner & Bass Inc. purchased a new stake in shares of IQVIA during the fourth quarter valued at $44,000. Zions Bancorporation N.A. boosted its position in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares during the period. Versant Capital Management Inc increased its stake in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in IQVIA during the 4th quarter worth about $60,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on IQV shares. Truist Financial decreased their target price on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a report on Thursday. Citigroup decreased their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Mizuho lowered their target price on IQVIA from $242.00 to $210.00 and set an “outperform” rating on the stock in a research note on Wednesday. Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Robert W. Baird lowered their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Six analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $241.50.

IQVIA Stock Up 1.5 %

Shares of IQV stock opened at $145.40 on Friday. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock’s 50 day simple moving average is $182.32 and its 200 day simple moving average is $199.64. The company has a market capitalization of $25.64 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.